CA3069019A1 - Pharmaceutical compositions, methods for preparation using lipid vesicle particles of defined size, and uses thereof - Google Patents

Pharmaceutical compositions, methods for preparation using lipid vesicle particles of defined size, and uses thereof Download PDF

Info

Publication number
CA3069019A1
CA3069019A1 CA3069019A CA3069019A CA3069019A1 CA 3069019 A1 CA3069019 A1 CA 3069019A1 CA 3069019 A CA3069019 A CA 3069019A CA 3069019 A CA3069019 A CA 3069019A CA 3069019 A1 CA3069019 A1 CA 3069019A1
Authority
CA
Canada
Prior art keywords
lipid
peptide
pharmaceutical composition
peptide antigens
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3069019A
Other languages
English (en)
French (fr)
Inventor
Leeladhar Sammatur
Rajkannan RAJAGOPALAN
Arthvan SHARMA
Valarmathy KALIAPERUMAL
Genevieve WEIR
Marianne Stanford
Andrea Penwell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HIMV LLC
Original Assignee
Immunovaccine Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovaccine Technologies Inc filed Critical Immunovaccine Technologies Inc
Publication of CA3069019A1 publication Critical patent/CA3069019A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3069019A 2017-07-10 2017-11-09 Pharmaceutical compositions, methods for preparation using lipid vesicle particles of defined size, and uses thereof Pending CA3069019A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762530498P 2017-07-10 2017-07-10
US62/530,498 2017-07-10
PCT/CA2017/051336 WO2019010560A1 (en) 2017-07-10 2017-11-09 PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION USING LIPID VESICLE PARTICLES OF A DEFINED SIZE, AND USES THEREOF

Publications (1)

Publication Number Publication Date
CA3069019A1 true CA3069019A1 (en) 2019-01-17

Family

ID=65000992

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3069019A Pending CA3069019A1 (en) 2017-07-10 2017-11-09 Pharmaceutical compositions, methods for preparation using lipid vesicle particles of defined size, and uses thereof

Country Status (7)

Country Link
US (1) US20200230057A1 (enExample)
EP (1) EP3651733A4 (enExample)
JP (1) JP7409594B2 (enExample)
CN (1) CN111093623A (enExample)
AU (1) AU2017423053A1 (enExample)
CA (1) CA3069019A1 (enExample)
WO (1) WO2019010560A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220241409A1 (en) * 2019-04-05 2022-08-04 Sumitomo Dainippon Pharma Co., Ltd. Water soluble adjuvant and composition containing same

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3768242A4 (en) * 2018-03-20 2021-12-08 ImmunoVaccine Technologies Inc. METHODS AND COMPOSITIONS FOR THE TARGETED DELIVERY OF ACTIVE SUBSTANCES AND IMMUNMODULATORY AGENTS TO LYMPH NODES
CN113329761A (zh) 2018-09-04 2021-08-31 特雷斯生物有限公司 肽疫苗
AU2020221280B2 (en) 2019-02-15 2026-04-23 Cleveland Clinic Foundation Vaccine adjuvants and formulations
BR112021023726A2 (pt) 2019-05-25 2022-02-15 Infectious Disease Res Inst Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
US20230348935A1 (en) * 2020-09-24 2023-11-02 Nant Holdings Ip, Llc Vaccine compositions for mucosal immune response
CA3197163A1 (en) * 2020-09-28 2022-03-31 Immunovaccine Technologies Inc. Lipid compositions comprising polynucleotide antigens

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2906110A (en) * 1959-09-29 Silencing attachment for seamless
JP4705591B2 (ja) * 2004-01-07 2011-06-22 バイオメディカル リサーチ モデルズ， インコーポレイテッド 抗原または免疫原に対する免疫応答を仕立てる方法。
CA2723918C (en) * 2008-06-05 2018-01-09 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
JP5429710B2 (ja) * 2009-03-30 2014-02-26 独立行政法人放射線医学総合研究所 治療薬剤の標的部位への集積及び放出を追跡可能な治療薬剤含有リポソームおよびその製造方法
KR101102834B1 (ko) * 2010-02-24 2012-01-05 충남대학교산학협력단 신규한 리포좀 제조 방법 및 장치
CU20100144A7 (es) * 2010-07-06 2012-06-21 Centro Inmunologia Molecular Composiciones vacunales a base de sticholisina encapsulada en liposomas
JP2014519496A (ja) * 2011-05-11 2014-08-14 ナノヴァレント ファーマシューティカルズ，インコーポレイテッド Ａｌｃａｍ細胞表面受容体を標的とする細胞毒性重合リポソームナノ粒子による増強された骨肉腫の増殖抑制
IN2014CN02581A (enExample) * 2011-10-06 2015-08-07 Immunovaccine Technologies Inc
PT2768484T (pt) * 2011-10-21 2019-10-28 Jazz Pharmaceuticals Res Llc Lipossomas liofilizados
CA2853689C (en) * 2011-11-04 2020-06-30 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
BR112015000174A2 (pt) * 2012-07-05 2017-06-27 Taiwan Liposome Co Ltd método para o tratamento da artrite
US9693958B2 (en) * 2013-03-15 2017-07-04 Cureport, Inc. Methods and devices for preparation of lipid nanoparticles
JP7028774B2 (ja) * 2015-08-19 2022-03-02 シャンハイ ギンポサム ファーマテック カンパニー リミテッド ギンセノシドを膜材料として有するリポソームならびにその調製および使用
US11160861B2 (en) * 2015-11-18 2021-11-02 Immunovaccine Technologies Inc. Adjuvanting systems and water-free vaccine compositions comprising a polyI:C polynucleotide adjuvant and a lipid-based adjuvant
WO2017097196A1 (zh) * 2015-12-08 2017-06-15 正大天晴药业集团股份有限公司 脂质体的制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220241409A1 (en) * 2019-04-05 2022-08-04 Sumitomo Dainippon Pharma Co., Ltd. Water soluble adjuvant and composition containing same

Also Published As

Publication number Publication date
WO2019010560A1 (en) 2019-01-17
JP7409594B2 (ja) 2024-01-09
EP3651733A1 (en) 2020-05-20
US20200230057A1 (en) 2020-07-23
CN111093623A (zh) 2020-05-01
EP3651733A4 (en) 2021-04-07
JP2020526530A (ja) 2020-08-31
AU2017423053A1 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
JP7409594B2 (ja) 医薬組成物、規定のサイズの脂質ベシクル粒子を使用する調製物のための方法、及びそれらの使用
JP6625587B2 (ja) Ｔｌｒ２を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
US20200353062A1 (en) Pharmaceutical compositions, methods for preparation comprising sizing of lipid vesicle particles, and uses thereof
JP6851983B2 (ja) デポー形成及びデポー非形成ワクチンを使用して免疫応答を強化する方法
JP6792452B2 (ja) 免疫原性化合物
US20230000769A1 (en) Oil-in-water emulsion formulations for delivery of active or therapeutic agents
JP2014528955A5 (enExample)
Khalifa et al. Subunit antigen delivery: emulsion and liposomal adjuvants for next-generation vaccines
WO2024102332A1 (en) Vaccine compositions comprising a neoantigen of kras
US20230381309A1 (en) Methods of treating diffuse large b-cell lymphoma
HK40035550A (en) Pharmaceutical compositions, methods for preparation comprising sizing of lipid vesicle particles, and uses thereof
WO2024186646A1 (en) Methods of making lipid adjuvanted compositions
WO2024186623A1 (en) Methods of making dried pharmaceutical compositions
US20240390468A1 (en) Survivin and mage-a9 dual-targeted immunotherapy
Trent A modular, multivalent, and multifunctional vaccine platform based on self-assembled peptide amphiphile micelles

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220830

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260105

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260130

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260130

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260511

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260619